Drugs such as Novo Nordisk’s Ozempic can cut drug and alcohol abuse by up to 50%, a study found, adding to mounting evidence ...

A trial, targeted at people living with obesity from Britain to Puerto Rico, is the first head-to-head comparison of the ...

Public interest groups are urging the FTC to block Novo Holdings' $16.5 billion acquisition of Catalent, citing concerns over ...

Novo Holdings is encountering more resistance as it aims to close its $16.5 billion acquisition of pharma manufacturing giant ...

Judge Karen Marston held that, despite plaintiffs' arguments to the contrary, marketing discovery is not relevant to the ...

GLP-1 receptor agonists and similar drugs may protect people with opioid or alcohol use disorder from opioid overdose and ...

Revolutionary weight management and diabetes medications could prove to be the next frontier in addiction recovery treatment medications.

Weight-loss drugs such as Ozempic, made by Denmark's Novo Nordisk, can reduce rates of opioid and alcohol abuse by up to 50%, according to a new study that supports expectations the drugs can offer ...

Paul Harris of Harris Douglas Asset Management says he hasn’t sold a stock since 2020. ‘I don’t feel the need to sell ...

We recently published an article titled, Jim Cramer’s Latest Lightning Round: 12 Stocks to Watch. In this article, we are ...

Giving older Americans access to weight-loss medicines through the US Medicare program would cost $35 billion over nine years, according to a congressional analysis. Expanding coverage of weight-loss ...

Novo Nordisk scientists have synthesised an insulin molecule that specifically targets glucose in blood, instead of other sugars like fructose, to aid treatment of all types of diabetes.